Aurobindo Pharma Limited

Total Valuation

Aurobindo Pharma Limited carries a market capitalization of 914.10B, placing it among publicly traded companies globally. Its enterprise value stands at 660.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Aurobindo Pharma Limited trades at a trailing price-to-earnings ratio of 19.46.

Enterprise Valuation

On an enterprise value basis, Aurobindo Pharma Limited trades at an EV/EBITDA multiple of 13.37 and an EV/FCF ratio of 217.11. The EV/Sales ratio of 2.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.37 provides insight into valuation relative to core operating earnings.

Financial Position

Aurobindo Pharma Limited maintains a current ratio of 3.68, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.60, indicating elevated leverage, while an interest coverage ratio of 11.12 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Aurobindo Pharma Limited has paid 15.60B in income taxes, reflecting an effective tax rate of 31.51.

Stock Price Statistics

Aurobindo Pharma Limited's stock has gained approximately 34.66442% over the past 52 weeks. The 50-day moving average sits at 1,191.50, while the 200-day moving average is 1,147.20.

Income Statement

Over the trailing twelve months, Aurobindo Pharma Limited generated 317.12B in revenue and converted that into 33.91B in net income, yielding earnings per share of 58.28. EBITDA reached 49.38B, while operating income came in at 49.38B.

Margins

Aurobindo Pharma Limited operates with a gross margin of 58.40, reflecting its pricing power and cost economics. The operating margin of 15.57 and net profit margin of 10.69 provide insight into operational efficiency.

Stock Splits

Aurobindo Pharma Limited's most recent stock split took place on July 20, 2015 with a 1:2 split ratio.

Scores

Aurobindo Pharma Limited posts an Altman Z-Score of 9.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.